Clopidogrel provides significantly greater inhibition of platelet activity than aspirin when combined with atorvastatin after coronary artery bypass grafting: A prospective randomized study

Clinical and Applied Thrombosis/Hemostasis

Volumn 16, Issue 2, 2010, Pages 189-198

  Tetik, Sermin ^a   Ak, Koray ^a   Isbir, Selim ^a   Eksioglu Demiralp, Emel ^a   Arsan, Sinan ^a   Iqbal, Omer ^b   Yardimci, Turay ^a  

^a MARMARA UNIVERSITY   (Turkey)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Acetylsalicylic acid; Atorvastatin; Clopidogrel; Coronary artery bypass graft; Flow cytometry; Platelet aggregation

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; LOW DENSITY LIPOPROTEIN; PADGEM PROTEIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BINDING; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME;

ADENOSINE DIPHOSPHATE; AGED; ASPIRIN; COMORBIDITY; CORONARY ARTERY BYPASS; CORONARY DISEASE; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOGEN; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; P-SELECTIN; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; PYRROLES; TICLOPIDINE;

EID: 77949894173     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029609344980     Document Type: Article

References (28)

1. Goyal A., Alexander JH, Hafley GE, et al, and the PREVENT IV Investigators. Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery. Ann Thorac Surg. 2007 ; 83 (3). 993-1001.
2. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 1997 ; 336 (3). 153-162.
3. Pan W., Pintar T., Anton J., Lee V., Vaughn WK, Collard CD Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery. Circulation. 2004 ; 110 (11 suppl 1). 1145-1149.
4. Dontani MI, Elnicki DM, Jain AC, Gibson CM Effect of preoperative statin therapy on cardiac outcomes after coronary artery bypass grafting. Am J Cardiol. 2000 ; 86 (10). 1128-1130, A6.
5. Chan AW, Bhatt DL, Chew DP, et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation. 2002 ; 105 (6). 691-696.
6. Poldermans D., Bax JJ, Kertai MD, et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation. 2003 ; 107 (14). 1848-1851.
7. Rosenson RS, Tangney CC Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA. 1998 ; 279 (20). 1643-1650.
8. Alexander JH, Harrington RA, Tuttle RH, et al. Prior aspirin use predicts worse outcomes in patients with non-ST elevation acute coronary syndromes. Am J Cardiol. 1999 ; 83 (8). 1147-1151.
9. Pereillo JM, Maftouh M., Andrieu A. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos. 2002 ; 30 (11). 1288-1295.
10. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation. Circulation. 2003 ; 107 (1). 32-37.
11. Brophy J., Costa V., Babapulle M. A pharmacoepidemiological study of the interaction between atorvastatin and clopidogrel following percutaneous coronary interventions. J Am Coll Cardiol. 2004 ; 43 (suppl A). 50A Abstract.
12. Vinholt P., Poulsen TS, Korsholm L., et al. The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease. Thromb Haemost. 2005 ; 94 (2). 438-443.
13. Smith SC Jr, Blair SN, Bonow RO, et al. AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 Update: a statement for healthcare professionals from the American Heart Association and the atherosclerotic cardiovascular disease. Circulation. 2001 ; 104 (13). 1577-1579.
14. Ak K., Atalan N., Tekeli A., et al. Thromboelastography and its use in cardiac surgery [in Turkish]. Anadolu Kardiyol Derg. 2008 ; 8 (2). 154-162.
15. Ak K., Isbir CS, Tetik S., et al. Thromboelastography-based transfusion algorithm reduces blood product use after elective CABG: a prospective randomized study. J Card Surg. 2009 ; 24 (4). 404-410.
16. Tetik S., Uras F., EkÅiolu-Demiralp E., Turay Yardimci K. Low-density lipoprotein specifically binds glycoprotein IIb/IIIa: a flow cytometric method for ligand-receptor interaction. Clin Appl Thrombos Hemostas. 2008 ; 14 (2). 210-219.
17. Stein PD, Dalen JE, Goldman S., Thároux P. Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts. Chest. 1998 ; 114 (5 suppl). 658S - 665S.
18. Hirsh J., Bhatt DL Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies. Arch Intern Med. 2004 ; 164 (19). 2106-2110.
19. Sanguigni V., Pignatelli P., Lenti L., et al. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation. 2005 ; 111 (4). 412-419.
20. Klinkhardt U., Bauersachs R., Adams J., Graff J., Lindhoff-Last E., Harder S. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clin Pharmacol Ther. 2003 ; 73 (3). 232-241.
21. Xiao Z., Thároux P. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J Am Coll Cardiol. 2004 ; 43 (11). 1982-1988.
22. Yao SK, Ober JC, Fergusson JJ, et al. Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis. Am J Physiol. 1994 ; 267 (2 pt 2). 488-493.
23. Moshfegh K., Redondo M., Julmy F., et al. Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy. J Am Coll Cardiol. 2000 ; 36 (3). 699-705.
24. Dietzen DJ, Page KL, Tetzloff TA, Bohrer A., Turk J. Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase blunts factor VIIa/tissue factor and prothrombinase activities via effects on membrane phosphatidylserine. Arterioscler Thromb Vasc Biol. 2007 ; 27 (3). 690-696.
25. Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M., Goudevenos JA, Tselepis AD Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concominantly for 5 weeks in patients with acute coronary syndromes. Circulation. 2004 ; 109 (11). 1335-1338.
26. Wierzbicki AS, Lumb PJ, Semra YK, Crook MA Effect of atorvastatin on plasma fibrinogen. Lancet. 1998 ; 351 (9102). 569-570.
27. Tetik S., Uras F., Yardimci KT Purification and characterization of human platelet fibrinogen receptor the GpIIb/IIIa complex. J Pharm Sci. 2005 ; 2 (3). 155-162.
28. Zimmermann N., Kienzle P., Weber AA, et al. Aspirin resistance after coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2001 ; 121 (5). 982-984.